[1]李振前,杨梦春,刘戎惠,等.扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究[J].陕西中医,2022,(8):1037-1040.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.011]
　LI Zhenqian,YANG Mengchun,LIU Ronghui,et al.Effect of Fuzheng Xiaoai decoction and Sijunzi decoction combined with capecitabine on patients with advanced colorectal cancer[J].,2022,(8):1037-1040.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.011]
点击复制

扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年8期
页码:
1037-1040
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Effect of Fuzheng Xiaoai decoction and Sijunzi decoction combined with capecitabine on patients with advanced colorectal cancer
作者:
李振前; 杨梦春; 刘戎惠; 吴福宁
(铜陵市中医医院,安徽 铜陵 244031)
Author(s):
LI Zhenqian; YANG Mengchun; LIU Ronghui; WU Funing
(Tongling Hospital of Traditional Chinese Medicine,Tongling 244031,China)
关键词:
晚期结直肠癌;  扶正消癌汤;  四君子汤;  卡培他滨;  癌胚抗原;  糖类抗原242
Keywords:
Advanced colorectal cancer;  Fuzheng Xiaoai decoction;  Sijunzi decoction;  Capecitabine;  Carcinoembryonic antigen;  Carbohydrate antigen 242
分类号:
R 735.37
DOI:
DOI:10.3969/j.issn.1000-7369.2022.08.011
文献标志码:
A
摘要:
目的:探讨扶正消癌汤合四君子汤联合卡培他滨对晚期结直肠癌患者的疗效及辅助性T细胞1(Th1)/辅助性T细胞2(Th2)水平的影响。方法:选取112例晚期结直肠癌患者,采用随机数字表法分为对照组(给予卡培他滨治疗)和联合组(给予扶正消癌汤合四君子汤+卡培他滨治疗),每组56例。比较两组患者治疗前后中医症候评分、临床疗效、Th1、Th2、Th1/Th2水平及肿瘤标志物[癌胚抗原(CEA)、糖类抗原242(CA242)]水平。比较两组患者治疗期间不良反应总发生率。结果:治疗后两组患者主症、次症评分和总分均降低(P<0.05),且联合组主症、次症评分和总分均低于对照组(P<0.05)。联合组客观缓解率高于对照组(P<0.05)。治疗后两组患者Th1、Th1/Th2水平均升高(P<0.05),且联合组Th1、Th1/Th2水平高于对照组(P<0.05); 治疗后两组患者Th2均降低(P<0.05),且联合组Th2低于对照组(P<0.05)。治疗后两组患者CEA、CA242水平均降低(P<0.05),且联合组CEA、CA242水平均低于对照组(P<0.05)。两组患者治疗期间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:采用扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌可有效缓解患者临床症状、提高临床疗效和免疫功能、降低肿瘤标志物水平。
Abstract:
Objective:To investigate the efficacy of Fuzheng Xiaoai decoction and Sijunzi decoction combined with capecitabine in patients with advanced colorectal cancer and the effect of T helper 1(Th1)/T helper 2(Th2)levels.Methods:A total of 112 patients with advanced colorectal cancer were selected and divided into the control group(treated with capecitabine)and the combined group(treated with Fuzheng Xiaoai decoction combined with Sijunzi decoction + capecitabine treatment)by random number table method,56 cases in each group.The TCM symptom scores,clinical efficacy,Th1,Th2,Th1/Th2 levels and tumor markers [carcinoembryonic antigen(CEA)and carbohydrate antigen 242(CA242)] levels were compared between the two groups before and after treatment.The overall incidence of adverse reactions during treatment in the two groups was compared.Results:After treatment,the scores of main symptoms,secondary symptoms and total scores of the two groups were decreased(P<0.05),and the scores of main symptoms,secondary symptoms and total scores of the combined group were lower than those of the control group(P<0.05).The objective remission rate in the combination group was higher than that in the control group(P<0.05).After treatment,the levels of Th1 and Th1/Th2 in the two groups were increased(P<0.05),and the Th1 and Th1/Th2 levels in the combined group were higher than those in the control group(P<0.05).Th2 in both groups decreased after treatment(P<0.05),and Th2 in the combined group was lower than that in the control group(P<0.05).After treatment,the levels of CEA and CA242 in the two groups were decreased(P<0.05),and the levels of CEA and CA242 in the combined group were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Fuzheng Xiaoai decoction and Sijunzi decoction combined with capecitabine in the treatment of advanced colorectal cancer can effectively relieve the clinical symptoms,improve the clinical efficacy and immune function,and reduce the level of tumor markers.

参考文献/References:

[1] 杨得振,侯俊明,惠 阳,等.当归补血汤联合卡培他滨节拍化疗治疗高龄晚期结直肠癌[J].吉林中医药,2019,39(8):1032-1036.
[2] 林增海,陆 军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医,2021,42(10):1338-1343.
[3] Lichtenstern CR,Ngu RK,Shalapour S,et al.Immunotherapy,inflammation and colorectal cancer [J].Cells,2020,9(3):618.
[4] 赵景文,毛 刚,王巨良,等.自拟消癌汤合四君子汤治疗晚期转移性直肠癌疗效及对生活质量、血清肿瘤标志物水平的影响[J].现代中西医结合杂志,2020,29(3):308-310,330.
[5] 邓婧靓,周留敏,周 琳.活血解毒汤联合火针治疗血瘀型银屑病疗效及对患者外周血Th1/Th2平衡的影响[J].陕西中医,2019,40(1):103-105.
[6] Saleh R,Taha RZ,Toor SM,et al.Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer [J].Cancer Immunol Immunother,2020,69(10):1989-1999.
[7] 国家卫生计生委医政医管局,中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2017年版)[J].中华外科杂志,2018,56(4):241-258.
[8] 李辰慧,赵文硕,冯 利,等.中医辨证维持治疗晚期结直肠癌的临床研究[J].北京中医药,2014,33(2):93-96.
[9] Rades D,Bolm L,Kaesmann L,et al.Karnofsky performance score is predictive of survival after palliative irradiation of metastatic bile duct cancer [J].Anticancer Res,2017,37(2):949-951.
[10] 朱伟明,陈玉超.陈玉超辨治中晚期大肠癌的中医辨证及方药规律总结[J].中医药导报,2018,24(4):36-38.
[11] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].European Journal of Cancer,2009,45(2):211-247.
[12] Wijnands AM,Jong ME,Lutgens MW,et al.Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease:Systematic review and meta-analysis [J].Gastroenterology,2021,160(5):1584-1598.
[13] 赵英旋,白玉勤.结直肠癌患者肿瘤出芽情况与临床病理特征、程序性死亡受体1及程序性死亡配体1表达相关性研究[J].陕西医学杂志,2021,50(6):747-751.
[14] Murakawa T.Past,present,and future perspectives of pulmonary metastasectomy for patients with advanced colorectal cancer [J].Surg Today,2021,51(2):204-211.
[15] 章玉玲,周 岳.结直肠癌患者血清循环肿瘤细胞、糖类抗原24-2、糖类抗原19-9水平及其与临床病理特征关系[J].陕西医学杂志,2022,51(3):322-324,329.
[16] 毛竹君,祝利民,卢艳琳,等.中医健脾法配合FOLFOX化疗方案对结肠癌术后患者癌因性疲乏、Th1/Th2免疫应答平衡及周围神经病变的影响[J].现代中西医结合杂志,2017,26(36):4027-4030.
[17] 宋 庆,张春盈,冯艳亮.扶正消积汤联合化疗治疗晚期结肠癌疗效观察及对肿瘤标记物、免疫功能指标的影响[J].福建中医药,2019,50(3):13-14,22.
[18] 邹瑜斌,杨 灵,肖池金,等.卡培他滨联合奥沙利铂对晚期结直肠癌患者血清肿瘤标志物水平的影响[J].中国当代医药,2020,27(24):124-126,130.
[19] 冯 禄,张艳辉,郭凯红.卡培他滨联合奥沙利铂治疗晚期结直肠癌的近远期疗效及对血清癌胚抗原、糖类抗原19-9表达水平的影响[J].癌症进展,2021,19(4):395-398.
[20] 迟艳飞.评价晚期结直肠癌患者联合化疗后卡培他滨维持治疗的临床疗效[J].中国保健营养,2020,30(24):262-265.
[21] 马园园,王 静,罗 琼,等.黄芪总皂苷药理作用研究进展[J].辽宁中医药大学学报,2020,22(7):1583-1587.
[22] 朱恒舟,桑天庆,季 漪,等.基于消癌解毒方中白花蛇舌草有效成分治疗肿瘤的靶点研究[J].中华中医药学刊,2020,38(5):132-135.
[23] 贾西贝,温林春,章龙珍.辅助性T细胞1与辅助性T细胞2比值及相关细胞因子对结直肠癌患者预后的影响[J].肿瘤研究与临床,2021,33(10):772-776.

相似文献/References:

[1]汪耔璇,李 烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究*[J].陕西中医,2020,(10):1414.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.020]
[2]周鹏飞,董晓琳,查名宝.清肠解毒方联合化疗治疗晚期结直肠癌疗效及对患者预后的影响[J].陕西中医,2024,(9):1226.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.017]
　ZHOU Pengfei,DONG Xiaolin,ZHA Mingbao.Clinical effect and prognosis of Qingchang Jiedu formula combined with chemotherapy in the treatment of patients with advanced colorectal cancer[J].,2024,(8):1226.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.017]

备注/Memo

备注/Memo:
基金项目:安徽省中医药管理局科研项目(2020CCYB17)
更新日期/Last Update: 2022-08-10